Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss treatments include finasteride, minoxidil, microneedling, dutasteride, CB-03-01, RU-58841, and experimental options like KY-19382 and stem cell therapy. Some treatments are considered ineffective or risky, such as ketoconazole, PRP, and low-level laser therapy.

The user experienced hair thinning after switching from topical to oral minoxidil while also using finasteride. They are considering returning to topical minoxidil due to lack of improvement with the oral version.

People are excited about a new hair loss treatment, PP405, and some suggest using Twitter to increase its visibility. Current treatments mentioned include finasteride, minoxidil, and dutasteride, but skepticism remains about the effectiveness of new treatments.

A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

PP405, a promising hair loss treatment, is expected to be available by 2027, with faster trials due to its topical nature. Users are eager for its release, comparing it to existing treatments like minoxidil and finasteride, but remain cautious about its long-term effectiveness.

The user has been using minoxidil, finasteride, and microneedling for two years, resulting in significant hair regrowth and plans for a 4000 graft hair transplant. The treatments have strengthened the donor area, making a hair transplant feasible.

The conversation humorously discusses the fictional "Post PP405 Syndrome" and the idea of starting a foundation or cult around it. It mentions skepticism about the effectiveness of PP405 and jokes about future therapies.

The conversation discusses hair regrowth progress using finasteride, with suggestions to add minoxidil and microneedling for better results. The user experienced noticeable improvement and plans to consider a hair transplant.

PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.

PP405 is a potential hair loss treatment that may work by blocking signals that cause hair cells to stop growing, requiring daily application for effectiveness. It could serve as an alternative to minoxidil and finasteride, but it is not yet available on the market and may take several years to be released.

The user experienced initial hair improvement with finasteride but noticed worsening hair loss after switching to dutasteride. They are considering returning to finasteride due to persistent hair shedding and scalp itch.

A new supplement for hair growth combines black rice, prickly pear, and saw palmetto, showing promising results in increasing hair density and reducing hair loss. The supplement is considered a drug-free alternative to traditional treatments like minoxidil and finasteride.

Pyrilutamide's long-term stability is uncertain, with potential degradation after 8-9 months if not stored properly. It's recommended to use fresh batches and store them in a cool, dark place.

The conversation discusses the need for a localized 5-alpha reductase inhibitor that only affects the scalp without systemic side effects, similar to pyrilutamide's approach. Current treatments like topical liposomal finasteride and dutasteride are mentioned, but concerns about their systemic effects and lack of research are highlighted.

A 25-year-old from Italy is experiencing hair thinning and seeks advice on obtaining finasteride, which requires a prescription in Italy. Suggestions include consulting a local doctor or using telehealth services.

Revivhair serum is discussed as a potential treatment for mild hair thinning, but skepticism exists about its effectiveness without proven treatments like finasteride, dutasteride, or minoxidil. Users share experiences with various treatments, noting side effects and exploring alternatives like topical dutasteride and alfatradiol.

A 20-year-old is experiencing aggressive hair loss and is using oral finasteride, oral minoxidil, red light therapy, and considering adding dutasteride. Users advise patience, consistency, and waiting 3-6 months for potential regrowth.

Some users maintained hair gains after stopping microneedling while continuing minoxidil and finasteride, while others saw no improvement or experienced hair breakage. One user switched to oral minoxidil and continued finasteride and dutasteride after seeing no results from microneedling.

Dutasteride treatment may decrease sperm concentration, but levels remain above WHO recommendations and recover after discontinuation. The study has limitations, including small sample size and lack of pre-treatment sperm data, and does not assess other fertility factors.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

A user experienced significant hair regrowth after improving their diet, getting sunlight, taking a multivitamin, and exercising, following a period of extreme calorie restriction and hair shedding. Others in the conversation attribute the hair regrowth to increased calorie intake rather than just vitamins.

Nizoral shampoo effectively reduces scalp itchiness and dandruff, particularly for those using minoxidil, and may promote hair growth despite not being FDA-approved for this purpose. Users report significant improvements in scalp health and reduced itchiness with regular use.

RootBioTec, a basil hairy root extract, claims to reduce hair loss by 31% in two months by inhibiting 5α reductase II and stimulating hair follicles. There is limited independent information available about its effectiveness.

A female with PCOS and androgenetic alopecia is starting treatment with oral Minoxidil, topical Minoxidil 5% with finasteride, and plans to add mesotherapy. She previously tried anti-androgenic contraceptive pills but couldn't tolerate them and is using Myo Inositol for weight management.

Topical finasteride can be as effective as oral finasteride for hair regrowth with fewer systemic side effects, but precise dosing is essential. Combining oral dutasteride with topical finasteride is not recommended due to dutasteride's stronger inhibition.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

Spironolactone may help reverse hair miniaturization in AGA. Combining it with minoxidil can promote thicker hair.

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.

There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.

Switching from finasteride to dutasteride can cause hair shedding, with mixed results; some see improvement, others see worsening. Using both treatments together initially may help reduce shedding.